Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
PROSCAR (finasteride) 5 mg tablets
Product / population
Adult BPH; oral 5 mg product.
Renal measure
Not specified; verify before use
Adult dose
The BPH dose is 5 mg orally once daily, with or without meals.
Renal statement
Renal impairment does not require a dose change. Label pharmacokinetic observations include creatinine clearance 9-55 mL/min; this range is evidence context, not a new dosing cutoff.
Source revision: | Retrieved: 2026-09-05. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Renal impairment does not require a dose change. Label pharmacokinetic observations include creatinine clearance 9-55 mL/min; this range is evidence context, not a new dosing cutoff.
UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.
Renal method: Not specified in this summary. Source date: Not established Retrieved: 2026-09-05
Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.
Renal-function and renal-replacement summary
The 20-50, 10-20 and <10 mL/min bands retain the normal dose. APD/CAPD, HD and CAV/VVHD are considered unlikely to remove finasteride; high-flux removal is unknown. The book retains normal dosing across these modalities.
finasteride-bph:rdh5-429-1 · Source locator: Dose in renal impairment; Dose in renal replacement
Lower-range evidence
The book notes label data down to CrCl 9 mL/min and no studies below 9. This is an evidence limitation rather than a studied-dose guarantee at every lower value.
finasteride-bph:rdh5-429-2 · Source locator: Other information
Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 429; PDF page 448
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.